The approval of Doptelet was based on results from the ADAPT-1 (N=231) and ADAPT-2 trials (N=204), 2 identically-designed multicenter, randomized, double-blind, placebo-controlled studies. The Food ...
The US Food and Drug Administration (FDA) has approved avatrombopag (Doptelet, AkaRx Inc) to increase platelet counts in adults with thrombocytopenia and chronic liver disease who are to undergo a ...
How Does Doptelet Work in Thrombocytopenia? Thrombocytopenia is when your blood has too few platelets (also called thrombocytes). Platelets are blood cells made in the soft, spongy tissue inside your ...
WASHINGTON -- The FDA approved another thrombopoietin receptor agonist on Monday, for an indication not covered by other drugs intended to raise platelet counts. The new agent is avatrombopag ...
What Is Doptelet, and Why Does It Matter? Doptelet (avatrombopag) is a prescription medicine that helps the body make more platelets (cells that help stop bleeding). First approved in 2018 for adults, ...
Thrombocytopenia (low platelet count) is common in people with cirrhosis. It can be caused by many factors, including an enlarged spleen and decreased platelet production. Severe thrombocytopenia can ...
Patients undergoing transcatheter aortic valve replacement (TAVR) have decreases in platelet counts that are typically transient, lasting just a few days. But in those with preexisting ...
Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback